Hester Biosciences Announces FY26 Financial Results; Profitability Surges Across Divisions
Hester Biosciences Limited announced the audited financial results for the quarter and the full fiscal year ended March 31, 2026. The company reported significant year-over-year growth in both standalone and consolidated performance, driven by robust operational execution and improved profitability across its key divisions.Standalone and Consolidated Financial Performance
The financial results for the year ended March 31, 2026, reflected a strong year for the company.Financial Highlights (INR Million)
| Particulars | Unit | Q4 FY26 | Q4 FY25 | Standalone Change % (Q4) | FY26 | FY25 | Standalone Change % (FY) |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | INR Million | 937.13 | 766.72 | 22% | 2,921.36 | 2,864.66 | 2% |
| Gross Profit Margin | % | 78% | 66% | 12% | 72% | 67% | 5% |
| EBITDA | INR Million | 426.40 | 147.60 | 189% | 871.03 | 557.08 | 56% |
| EBITDA% | % | 46% | 19% | 27% | 30% | 19% | 11% |
| PAT | INR Million | 263.84 | 96.35 | 174% | 521.00 | 318.42 | 64% |
| PAT% | % | 28% | 13% | 15% | 18% | 11% | 7% |
| EPS (in INR) | INR | 31.01 | 11.33 | 174% | 61.24 | 37.43 | 64% |
| Particulars | Unit | Q4 FY26 | Q4 FY25 | Consolidated Change % (Q4) | FY26 | FY25 | Consolidated Change % (FY) |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | INR Million | 1,001.10 | 819.25 | 22% | 3,325.99 | 3,111.02 | 7% |
| Gross Profit Margin | % | 81% | 75% | 6% | 75% | 72% | 3% |
| EBITDA | INR Million | 360.97 | 135.41 | 167% | 1,056.51 | 690.76 | 53% |
| EBITDA% | % | 36% | 17% | 19% | 32% | 22% | 10% |
| PAT | INR Million | 165.46 | 15.41 | 974% | 574.84 | 288.26 | 99% |
| PAT% | % | 17% | 2% | 15% | 17% | 9% | 8% |
| EPS (in INR) | INR | 19.45 | 1.82 | 974% | 67.57 | 33.89 | 99% |
Divisional and Operational Updates
The company's performance was largely supported by its Poultry Healthcare Division, which recorded strong growth during Q4 and FY26, driven by improved market penetration, expanded placements, and sustained demand for vaccines.The standalone divisional revenue saw growth metrics across the sectors:
| Divisions | FY26 Revenue (INR Million) | FY25 Revenue (INR Million) | Change % (Q4) | FY26 Revenue (INR Million) | FY25 Revenue (INR Million) | Change % (FY) |
|---|---|---|---|---|---|---|
| Poultry Healthcare | 2,060.79 | 1,664.39 | 41% | 650.20 | 460.85 | 41% |
| Animal Healthcare | 818.32 | 1,198.83 | -6% | 286.41 | 305.37 | -6% |
The company noted that while the Animal Healthcare Division continued to face impacts from delays in government immunisation programmes and uneven demand in certain commercial markets, the overall divisional product sales saw a 22% increase in Q4.
Operationally, the company reported several key milestones. During the quarter, it capitalized its BSL 3 facility as part of ongoing capacity expansion and infrastructure strengthening initiatives. Furthermore, it received marketing and manufacturing licenses for its H9N2 Avian Influenza vaccine, bolstering its poultry vaccine portfolio.
Board Approvals and Dividend Recommendation
The Board of Directors approved several key corporate actions:1. Financial Results: Approval of the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
2. Dividend: The board recommended a dividend of INR 11 (Eleven) per equity share of INR 10 each (110%) for the financial year 2025-26. This recommendation is subject to approval by the members at the ensuing Annual General Meeting.
3. Director Re-appointment: The Board also recommended the re-appointment of Ms. Priya Gandhi as Executive Director of the Company for a term of three years, effective from October 28, 2026.
Strategic Focus and Future Growth
Hester Biosciences stated that FY26 marked a year of operational strengthening and capacity expansion. Moving forward, the company remains focused on several key objectives:- Strengthening its biologicals portfolio across both poultry and animal healthcare.
- Improving market penetration in both domestic and export markets.
- Enhancing operational efficiency across functions and reducing dependence on institutional business through portfolio diversification.
The company continues to deepen its presence across Africa and other export markets by executing market development initiatives and forming strategic partnerships.
HESTERBIO Stock Price Movement
Shares of Hester Biosciences Limited are edging higher to ₹1960 as of 12:31 PM today, rallying 12.63% in live trading, translating to a gain of ₹219.80. The stock has seen a substantial trading volume of 103,337 shares throughout the session so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.